# US 2026/0159839 A1 · Pharmaceutical composition for treating spinocerebellar ataxia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0159839 A1
- Document ID: US20260159839A1
- Status: Published application
- Kind: A1
- Application number: 18/706,530
- Filed: 2022-11-07
- Published: 2026-06-11
- Earliest claimed: 2021-11-08
- Assignees: National University Corporation Tokyo Medical and Dental University
- Applicants: National University Corporation Tokyo Medical and Dental University
- Inventors: Takanori YOKOTA; Kinya ISHIKAWA; Tetsuya NAGATA; Miwa HIGASHI; Kotaro YOSHIOKA; Makoto KOIZUMI; Yoshiyuki ONISHI; Takao SHOJI
- Web page: https://patentgrep.com/patent/US20260159839A1

## CPC

- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/11: Antisense
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/341: Gapmers, i.e. of the type ===---===
- C12N 2310/3515: Lipophilic moiety, e.g. cholesterol
- C12N 2320/34: Allele or polymorphism specific uses
- C12Y 207/01021: Thymidine kinase (2.7.1.21)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

A nucleic acid molecule is provided having an antisense effect on the transcriptional product of a mutant gene having an abnormal repeat region. The abnormal repeat region has a 5′ region, a core repeat region, and a 3′ region. The core repeat region has a base sequence having multiple repeats of the base sequence TGGAA or a base sequence complementary thereto. The nucleic acid molecule includes a base sequence complementary to four or more consecutive bases in the abnormal repeat region in the transcriptional product and has a target binding region that is capable of hybridizing to the transcriptional product.

## Claims

### Claim 1

A nucleic acid molecule having an antisense effect on the transcriptional product of a mutant gene comprising an abnormal repeat region, wherein:
said abnormal repeat region consists of a 5′ region, a core repeat region, and a 3′ region,
said core repeat region consists of a base sequence consisting of multiple repeats of the base sequence TGGAA or a base sequence complementary thereto, and
said nucleic acid molecule comprises a base sequence complementary to four or more consecutive bases in said abnormal repeat region in said transcriptional product, and comprises a target binding region that is capable of hybridizing to said transcriptional product.

### Claim 2 (depends on 1)

The nucleic acid molecule of claim 1, wherein said mutant gene is a mutant form of the Brain Expressed Associated With NEDD4 1 (BEAN1) gene, said core repeat region consists of a base sequence consisting of multiple repeats of the base sequence TGGAA, and said 5′ region comprises the base sequence TCAC.

### Claim 3 (depends on 2)

The nucleic acid molecule of claim 2, wherein said 5′ region consists of a base sequence selected from the group consisting of the following (a1) to (a4):
(a1) the base sequence of SEQ ID NO: 3;
(a2) the base sequence of SEQ ID NO: 4;
(a3) the base sequence TCAC; and
(a4) a base sequence formed by linking the base sequence TCAC and a base sequence consisting of multiple repeats of the base sequence TAGAA from 5′ side in this order.

### Claim 4 (depends on 1)

The nucleic acid molecule of claim 1, wherein said mutant gene is a mutant form of the Brain Expressed Associated With NEDD4 1 (BEAN1) gene, said core repeat region consists of a base sequence consisting of multiple repeats of the base sequence TGGAA, and said 3′ region comprises a sequence consisting of multiple repeats of the base sequence TAGAA and a sequence consisting of multiple repeats of the base sequence of SEQ ID NO: 6.

### Claim 5 (depends on 4)

The nucleic acid molecule of claim 4, wherein said 3′ region consists of a base sequence selected from the group consisting of the following (b1) to (b5):
(b1) a base sequence formed by linking the base sequence of SEQ ID NO: 7, a base sequence consisting of multiple repeats of the base sequence TAGAA, and a base sequence consisting of multiple repeats of the base sequence of SEQ ID NO: 6, from 5′ side in this order;
(b2) a base sequence formed by linking the base sequence of SEQ ID NO: 9, a base sequence consisting of multiple repeats of the base sequence TAGAA, and a base sequence consisting of multiple repeats of the base sequence of SEQ ID NO: 6, from 5′ side in this order;
(b3) a base sequence formed by linking the base sequence of SEQ ID NO: 11, a base sequence consisting of multiple repeats of the base sequence TAGAA, and a base sequence consisting of multiple repeats of the base sequence of SEQ ID NO: 6, from 5′ side in this order;
(b4) a base sequence formed by linking the base sequence of SEQ ID NO: 12, a base sequence consisting of multiple repeats of the base sequence TAGAA, a base sequence consisting of multiple repeats of the base sequence of SEQ ID NO: 6, and a base sequence consisting of multiple repeats of the base sequence of SEQ ID NO: 13, from 5′ side in this order; and
(b5) a base sequence formed by linking the base sequence of SEQ ID NO: 14, a base sequence consisting of multiple repeats of the base sequence TAGAA, and a base sequence consisting of multiple repeats of the base sequence of SEQ ID NO: 6, from 5′ side in this order.

### Claim at position 6

-8. (canceled)

### Claim 9 (depends on 2)

The nucleic acid molecule of claim 2, which consists of a base sequence selected from the group consisting of SEQ ID NOs: 156 to 189 and 207 to 209, provided that “t” in the sequence may be “u”.

### Claim 10 (depends on 1)

The nucleic acid molecule of claim 1, wherein said mutant gene is a mutant form of the Thymidine Kinase 2 (TK2) gene, said core repeat region consists of the base sequence which is complementary to a base sequence consisting of multiple repeats of the base sequence TGGAA, and said 5′ region comprises a sequence consisting of multiple repeats of the base sequence of SEQ ID NO: 16 and a sequence consisting of multiple repeats of the base sequence TTCTA.

### Claim 11 (depends on 10)

The nucleic acid molecule of claim 10, wherein said 5′ region consists of any base sequence selected from the group consisting of the following (c1) to (c5):
(c1) a base sequence formed by linking a base sequence consisting of multiple repeats of the base sequence of SEQ ID NO: 16, a base sequence consisting of multiple repeats of the base sequence TTCTA, and the base sequence of SEQ ID NO: 19 from 5′ side in this order;
(c2) a base sequence formed by linking a base sequence consisting of multiple repeats of the base sequence of SEQ ID NO: 16, a base sequence consisting of multiple repeats of the base sequence TTCTA, and the base sequence of SEQ ID NO: 21 from 5′ side in this order;
(c3) a base sequence formed by linking a base sequence consisting of multiple repeats of the base sequence of SEQ ID NO: 16, a base sequence consisting of multiple repeats of the base sequence TTCTA, and the base sequence of SEQ ID NO: 22 from 5′ side in this order;
(c4) a base sequence formed by linking the base sequence of SEQ ID NO: 23, a base sequence consisting of multiple repeats of the base sequence of SEQ ID NO: 16, a base sequence consisting of multiple repeats of the base sequence TTCTA, and the base sequence of SEQ ID NO: 24 from 5′ side in this order; and
(c5) a base sequence formed by linking a base sequence consisting of multiple repeats of the base sequence of SEQ ID NO: 16, a base sequence consisting of multiple repeats of the base sequence TTCTA, and the base sequence of SEQ ID NO: 29 from 5′ side in this order.

### Claim 12 (depends on 1)

The nucleic acid molecule of claim 1, wherein said mutant gene is a mutant form of the Thymidine Kinase 2 (TK2) gene, said core repeat region consists of the base sequence which is complementary to a base sequence consisting of multiple repeats of the base sequence TGGAA, and said 3′ region comprises the base sequence GTGA.

### Claim 13 (depends on 12)

The nucleic acid molecule of claim 12, wherein said 3′ region consists of a base sequence selected from the group consisting of the following (d1) to (d4):
(d1) the base sequence of SEQ ID NO: 27;
(d2) the base sequence of SEQ ID NO: 28;
(d3) the base sequence GTGA; and
(d4) the base sequence formed by linking a base sequence consisting of multiple repeats of the base sequence TTCTA and the base sequence GTGA from 5′ side in this order.

### Claim at position 12

-16. (canceled)

### Claim 17 (depends on 10)

The nucleic acid molecule of claim 10, which consists of a base sequence selected from the group consisting of SEQ ID NOs: 33 to 53, 58 to 139, 141 to 150, 152 to 155, and 204 to 206, provided that “t” in the sequence may be “u”.

### Claim 18 (depends on 1)

The nucleic acid molecule of claim 1, wherein said mutant gene is a mutant form of the Ataxin 10 (ATXN10) gene, said core repeat region consists of the base sequence which is complementary to a base sequence consisting of multiple repeats of the base sequence TGGAA, and the full-length of said target binding region is comprised in the base sequence complementary to said core repeat region.

### Claim 19 (depends on 18)

The nucleic acid molecule of claim 18, which consists of a base sequence selected from the group consisting of SEQ ID NOs: 33 to 37, 58 to 61, 64 to 67, 70 to 139, 141 to 150, 152 to 155, and 204 to 206, provided that “t” in the sequence may be “u”.

### Claim at position 16

-21. (canceled)

### Claim 22 (depends on 1)

The nucleic acid molecule of claim 1, which is a gapmer.

### Claim at position 18

-32. (canceled)

### Claim 33 (depends on 1)

A double-stranded nucleic acid complex comprising a first nucleic acid strand consisting of the nucleic acid molecule of claim 1 and a second nucleic acid strand comprising a base sequence complementary to said first nucleic acid strand.

### Claim at position 20

-41. (canceled)

### Claim 42 (depends on 33)

The double-stranded nucleic acid complex of claim 33, wherein said second nucleic acid strand comprises one or more 2′-O-methoxyethyl-modified nucleosides.

### Claim 43 (depends on 42)

The double-stranded nucleic acid complex of claim 42, wherein at least 20% of the total number of nucleosides in said second nucleic acid strand are 2′-O-methoxyethyl-modified nucleosides.

### Claim at position 23

-48. (canceled)

### Claim 49 (depends on 33)

The double-stranded nucleic acid complex of claim 33, wherein said second nucleic acid strand is bound to tocopherol or cholesterol or an analog thereof.

### Claim 50 (depends on 33)

The double-stranded nucleic acid complex of claim 33, wherein:
the base sequence of said first nucleic acid strand consists of the base sequence of SEQ ID NO: 65, provided that “t” in the sequence may be “u”, and
the base sequence of said second nucleic acid strand consists of any a base sequence selected from the group consisting of SEQ ID NO: 140, SEQ ID NO: 200, SEQ ID NO: 201, SEQ ID NO: 202, and SEQ ID NO: 203, provided that “t” in the sequence may be “u”.

### Claim 51 (depends on 50)

The double-stranded nucleic acid complex of claim 50, wherein:
said first nucleic acid strand consists of the nucleic acid strand of SEQ ID NO: 65, and
said second nucleic acid strand consists of a nucleic acid strand selected from the group consisting of SEQ ID NO: 140, SEQ ID NO: 200, SEQ ID NO: 201, SEQ ID NO: 202, and SEQ ID NO: 203.

### Claim at position 27

-61. (canceled)
